On December 16, 2025, Akari Therapeutics Plc announced it raised approximately $9 million through a combination of cash proceeds and liability reduction via a registered direct offering and a private placement. This includes roughly $5 million in cash from selling 10,043,774 American Depositary Shares and about $4 million in note principal reduction through equity exchanges.